The use of multi-target drugs in the treatment of neurodegenerative diseases

References

• Burgut FT, Benaur M, Hencliffe C. Late-life depression: a neuropsychiatric approach. Expert Rev. Neurother.6(1), 65–72 (2006).
   PubMed Web of Science ®Google Scholar
• Cummings JL, Zhong K. Treatments for behavioural disorders in neurodegenerative diseases: drug development strategies. Nat. Rev. Drug Discov.5(1), 64–74 (2006).
   PubMed Web of Science ®Google Scholar
• Jellinger KA. Basic mechanisms of neurodegeneration: a critical update. J. Cell. Mol. Med.14(3), 457–487 (2010).
   PubMed Web of Science ®Google Scholar
• Cavallucci V, D’Amelio M. Matter of life and death: the pharmacological approaches targeting apoptosis in brain diseases. Curr. Pharm. Des.17(3), 215–229 (2011).
   PubMed Web of Science ®Google Scholar
• Lang AE. Clinical trials of disease-modifying therapies for neurodegenerative diseases: the challenges and the future. Nat. Med.16(11), 1223–1226 (2010).
   PubMed Web of Science ®Google Scholar
• Ferreira IL, Resende R, Ferreiro E et al. Multiple defects in energy metabolism in Alzheimer’s disease. Curr. Drug Targets11(10), 1193–1206 (2010).
   PubMed Web of Science ®Google Scholar
• Piau A, Nourhashémi F, Hein C et al. Progress in the development of new drugs in Alzheimer’s disease. J. Nutr. Health Aging15(1), 45–57 (2011).
   PubMed Web of Science ®Google Scholar
• Van der Schyf CJ, Youdim MB. Multifunctional drugs as neurotherapeutics. Neurotherapeutics6(1), 1–3 (2009).
   PubMed Web of Science ®Google Scholar
• Pruss RM. Phenotypic screening strategies for neurodegenerative diseases: a pathway to discover novel drug candidates and potential disease targets or mechanisms. CNS Neurol. Disord. Drug Targets9(6), 693–700 (2010).
   PubMed Web of Science ®Google Scholar
• Levy OA, Malagelada C, Greene LA. Cell death pathways in Parkinson’s disease: proximal triggers, distal effectors, and final steps. Apoptosis14(4), 478–500 (2009).
   PubMed Web of Science ®Google Scholar
• Bar-Am O, Amit T, Weinreb O et al. Propargylamine containing compounds as modulators of proteolytic cleavage of amyloid-β protein precursor: involvement of MAPK and PKC activation. J. Alzheimers Dis.21(2), 361–371 (2010).
   PubMed Web of Science ®Google Scholar
• Van der Schyf CJ, Geldenhuys WJ, Youdim MB. Multifunctional drugs with different CNS targets for neuropsychiatric disorders. J. Neurochem.99(4), 1033–1048 (2006).
   PubMed Web of Science ®Google Scholar
• Chertkow Y, Weinreb O, Youdim MB et al. Molecular mechanisms underlying synergistic effects of SSRI-antipsychotic augmentation in treatment of negative symptoms in schizophrenia. J. Neural Transm.116(11), 1529–1541 (2009).
   PubMed Web of Science ®Google Scholar
• Rutherford GW, Sangani PR, Kennedy GE. Three- or four- versus two-drug antiretroviral maintenance regimens for HIV infection. Cochrane Database Syst. Rev.4, CD002037 (2003).
   PubMedGoogle Scholar
• Chung KF, Adcock IM. Combination therapy of long-acting β2-adrenoceptor agonists and corticosteroids for asthma. Treat. Respir. Med.3(5), 279–289 (2004).
   PubMedGoogle Scholar
• Frishman WH, Zuckerman AL. Amlodipine/atorvastatin: the first cross risk factor polypill for the prevention and treatment of cardiovascular disease. Expert Rev. Cardiovasc. Ther.2(5), 675–681 (2004).
   PubMedGoogle Scholar
• Zerkak D, Dougados M. Benefit/risk of combination therapies. Clin. Exp. Rheumatol.22(5 Suppl. 35), S71–S76 (2004).
   PubMed Web of Science ®Google Scholar
• Keith CT, Borisy AA, Stockwell BR. Multicomponent therapeutics for networked systems. Nat. Rev. Drug Discov.4(1), 71–78 (2005).
   PubMed Web of Science ®Google Scholar
• Smid P, Coolen HK, Keizer HG et al. Synthesis, structure-activity relationships, and biological properties of 1-heteroaryl-4-[ω-(1H-indol-3-yl)alkyl]piperazines, novel potential antipsychotics combining potent dopamine D2 receptor antagonism with potent serotonin reuptake inhibition. J. Med. Chem.48(22), 6855–6869 (2005).
   PubMed Web of Science ®Google Scholar
• Schmitt B, Bernhardt T, Moeller HJ et al. Combination therapy in Alzheimer’s disease: a review of current evidence. CNS Drugs18(13), 827–844 (2004).
   PubMed Web of Science ®Google Scholar
• Holmes HM, Sachs GA, Shega JW et al. Integrating palliative medicine into the care of persons with advanced dementia: identifying appropriate medication use. J. Am. Geriatr. Soc.56(7), 1306–1311 (2008).
   PubMed Web of Science ®Google Scholar
• Morphy R, Rankovic Z. Designed multiple ligands. An emerging drug discovery paradigm. J. Med. Chem.48(21), 6523–6543 (2005).
   PubMed Web of Science ®Google Scholar
• Morphy R, Rankovic Z. Designing multiple ligands – medicinal chemistry strategies and challenges. Curr. Pharm. Des.15(6), 587–600 (2009).
   PubMed Web of Science ®Google Scholar
• Stahl SM. Multifunctional drugs: a novel concept for psychopharmacology. CNS Spectr.14(2), 71–73 (2009).
   PubMed Web of Science ®Google Scholar
• Youdim MB, Van der Schyf CJ. Magic bullets or novel multimodal drugs with various targets for Parkinson’s disease? Nat. Rev. Drug Discov.6(6), iii–vi (2007).
   Google Scholar
• Bolognesi ML, Matera R, Minarini A et al. Alzheimer’s disease: new approaches to drug discovery. Curr. Opin. Chem. Biol.13(3), 303–308 (2009).
   PubMed Web of Science ®Google Scholar
• Bolognesi ML, Rosini M, Andrisano V. MTDL design strategy in the context of Alzheimer’s disease: from lipocrine to memoquin and beyond. Curr. Pharm. Des.15(6), 601–613 (2009).
   PubMed Web of Science ®Google Scholar
• Durrant JD, Amaro RE, Xie L et al. A multidimensional strategy to detect polypharmacological targets in the absence of structural and sequence homology. PLoS Comput. Biol.6(1), e1000648 (2010).
   PubMed Web of Science ®Google Scholar
• Schrattenholz A, Groebe K, Soskic V. Systems biology approaches and tools for analysis of interactomes and multi-target drugs. Methods Mol. Biol.662, 29–58 (2010).
   PubMedGoogle Scholar
• Tsuji S. Genetics of neurodegenerative diseases: insights from high-throughput resequencing. Hum. Mol. Genet.19(R1), R65–R70 (2010).
   PubMed Web of Science ®Google Scholar
• Bolognesi ML, Banzi R, Bartolini M et al. Novel class of quinone-bearing polyamines as multi-target-directed ligands to combat Alzheimer’s disease. J. Med. Chem.50(20), 4882–4897 (2007).
   PubMed Web of Science ®Google Scholar
• Bolognesi ML, Cavalli A, Melchiorre C. Memoquin: a multi-target-directed ligand as an innovative therapeutic opportunity for Alzheimer’s disease. Neurotherapeutics6(1), 152162 (2009).
   Google Scholar
• Bolognesi ML, Bartolini M, Rosini M et al. Structure–activity relationships of memoquin: influence of the chain chirality in the multi-target mechanism of action. Bioorg. Med. Chem. Lett.19(15), 4312–4315 (2009).
   PubMed Web of Science ®Google Scholar
• Bolognesi ML, Cavalli A, Bergamini C et al. Toward a rational design of multitarget-directed antioxidants: merging memoquin and lipoic acid molecular frameworks. J. Med. Chem.52(23), 7883–7886 (2009).
   PubMed Web of Science ®Google Scholar
• Bolognesi ML, Bartolini M, Tarozzi A. Multitargeted drugs discovery: balancing anti-amyloid and anticholinesterase capacity in a single chemical entity. Bioorg. Med. Chem. Lett. DOI: 10.1016/j.bmcl.2010.12.093 (2010) (Epub ahead of print).
   Google Scholar
• Weinstock M, Bejar C, Wang RH et al. TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer’s disease. J. Neural. Transm. Suppl.60, 157–169 (2000).
   PubMedGoogle Scholar
• Weinreb O, Amit T, Bar-Am O et al. The neuroprotective mechanism of action of the multimodal drug ladostigil. Front. Biosci.13, 5131–5137 (2008).
   PubMed Web of Science ®Google Scholar
• Sagi Y, Weinstock M, Youdim MB. Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor. J. Neurochem.86(2), 290–297 (2003).
   PubMed Web of Science ®Google Scholar
• Youdim MB, Buccafusco JJ. CNS targets for multi-functional drugs in the treatment of Alzheimer’s and Parkinson’s diseases. J. Neural Transm.112(4), 519–537 (2005).
   PubMed Web of Science ®Google Scholar
• Magaki S, Raghavan R, Mueller C et al. Iron, copper, and iron regulatory protein 2 in Alzheimer’s disease and related dementias. Neurosci. Lett.418(1), 72–76 (2007).
   PubMed Web of Science ®Google Scholar
• Zheng H, Weiner LM, Bar-Am O et al. Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer’s, Parkinson’s, and other neurodegenerative diseases. Bioorg. Med. Chem.13(3), 773–783 (2005).
   PubMed Web of Science ®Google Scholar
• Youdim MB, Stephenson G, Ben Shachar D. Ironing iron out in Parkinson’s disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28. Ann. NY Acad. Sci.1012, 306–325 (2004).
   PubMed Web of Science ®Google Scholar
• Van der Schyf CJ, Gal S, Geldenhuys WJ et al. Multifunctional neuroprotective drugs targeting monoamine oxidase inhibition, iron chelation, adenosine receptors, and cholinergic and glutamatergic action for neurodegenerative diseases. Expert Opin. Investig. Drugs.15(8), 873–886 (2006).
   PubMed Web of Science ®Google Scholar
• Chimenti F, Bolasco A, Manna F et al. Synthesis, biological evaluation and 3D-QSAR of 1,3,5-trisubstituted-4,5-dihydro-(1H)-pyrazole derivatives as potent and highly selective monoamine oxidase A inhibitors. Curr. Med. Chem.13(12), 1411–1428 (2006).
   PubMed Web of Science ®Google Scholar
• Choi JS, Braymer JJ, Nanga RP, Ramamoorthy A, Lim MH. Design of small molecules that target metal-Aβ species and regulate metal-induced Aβ aggregation and neurotoxicity. Proc. Natl Acad. Sci. USA107(51), 21990–21995 (2010).
   PubMed Web of Science ®Google Scholar
• Mancino AM, Hindo SS, Kochi A et al. Effects of clioquinol on metal-triggered amyloid-β aggregation revisited. Inorg. Chem.48(20), 9596–9598 (2009).
   PubMed Web of Science ®Google Scholar
• Hindo SS, Mancino AM, Braymer JJ et al. Small molecule modulators of copper-induced Aβ aggregation. J. Am. Chem. Soc.131(46), 16663–16665 (2009).
   PubMed Web of Science ®Google Scholar
• Frédérick R, Ooms F, Castagnoli N Jr et al. (E)-8-(3-chlorostyryl)-1,3,7-trimethylxanthine, a caffeine derivative acting both as antagonist of adenosine A2A receptors and as inhibitor of MAO-B. Acta Crystallogr. C61(Pt 9), O531–O532 (2005).
   PubMedGoogle Scholar
• Dall’Igna OP, Fett P, Gomes MW et al. Caffeine and adenosine A2A receptor antagonists prevent β-amyloid (25–35)-induced cognitive deficits in mice. Exp. Neurol.203(1), 241–245 (2007).
   PubMed Web of Science ®Google Scholar
• Prediger RD, Batista LC, Takahashi RN. Caffeine reverses age-related deficits in olfactory discrimination and social recognition memory in rats. Involvement of adenosine A1 and A2A receptors. 26(6), 957–964 (2005).
   Google Scholar
• Petzer JP, Castagnoli N Jr, Schwarzschild MA et al. Dual-target-directed drugs that block monoamine oxidase B and adenosine A2A receptors for Parkinson’s disease. Neurotherapeutics6(1), 141–151 (2009).
   PubMed Web of Science ®Google Scholar
• Krieglstein J, Lippert K, Pöch G. Apparent independent action of nimodipine and glutamate antagonists to protect cultured neurons against glutamate-induced damage. Neuropharmacology35(12), 1737–1742 (1996).
   PubMed Web of Science ®Google Scholar
• Stuiver BT, Douma BR, Bakker R et al. In vivo protection against NMDA-induced neurodegeneration by MK-801 and nimodipine: combined therapy and temporal course of protection. Neurodegeneration5(2), 153–159 (1996).
   PubMedGoogle Scholar
• Kiewert C, Hartmann J, Stoll J et al. NGP1-01 is a brain-permeable dual blocker of neuronal voltage- and ligand-operated calcium channels. Neurochem. Res.31(3), 395–399 (2006).
   PubMed Web of Science ®Google Scholar
• Geldenhuys WJ, Malan SF, Bloomquist JR et al. Structure-activity relationships of pentacycloundecylamines at the N-methyl-D-aspartate receptor. Bioorg. Med. Chem.15(3), 1525–1532 (2007).
   PubMed Web of Science ®Google Scholar
• Van der Schyf CJ, Geldenhuys WJ. Polycyclic compounds: ideal drug scaffolds for the design of multiple mechanism drugs? Neurotherapeutics6(1), 175–186 (2009).
   PubMed Web of Science ®Google Scholar